Focusing on green, safe and high-performance fine chemical innovation, kehonda has continuously launched new high-quality products to meet the upgrading market demand. The company’s professional R&D team has successfully developed a new series of compound amino acid zinc deodorant raw materials, which are made from natural amino acids and activated zinc, featuring high safety, stable performance and efficient deodorizing effect.
We also keep optimizing and upgrading product lines covering cosmetic raw materials, industrial functional additives, pharmaceutical excipients, veterinary disinfectants and special surfactants. All new products comply with strict international quality and regulatory standards, and are widely used in daily chemicals, industrial energy, animal health, fire fighting, petrochemical and other fields, providing targeted solutions for global customers.
Hotspot mutations in isocitrate dehydrogenase 1 ( IDH1) and isocitrate dehydrogenase 2 ( IDH2) occur in a variety of myeloid malignancies and solid tumors. Mutant IDH proteins acquire a neomorphic enzyme activity to produce the putative oncometabolite D-2-hydroxyglutarate, which is thought to block cellular differentiation by competitively inhibiting α-ketoglutarate-dependent dioxygenases involved in histone and DNA demethylation. Small-molecule inhibitors of mutant IDH1 and IDH2 have been developed and are progressing through pre-clinical and clinical development. In this review, we provide an overview of mutant IDH-targeted therapy and discuss a number of important recent pre-clinical studies using models of IDH-mutant solid tumors.
